TEST FORMS – introduction

|  |
| --- |
| Name:      Name of laboratory:      Name of institute:      City:      Country:      E-mail:       |

#### Comments:

#### **TEST FORM *– Salmonella***

Survey on breakpoints applied routinely for antimicrobial susceptibility testing of *Salmonella*

|  |  |
| --- | --- |
| Antimicrobial  | Interpretation, Zone diameter (mm) or MIC-value (μg/ml) |
| <, ≤ | Susceptible | Intermediate | >, ≥ | Resistant |
| Ampicillin, AMP |       |       |       |       |       |
| Cefotaxime, CTX |       |       |       |       |       |
| Cefoxitin, FOX |       |       |       |       |       |
| Ceftazidime, CAZ |       |       |       |       |       |
| Ceftriaxone, CRO |       |       |       |       |       |
| Chloramphenicol, CHL |       |       |       |       |       |
| Ciprofloxacin, CIP |       |       |       |       |       |
| Colistin, COL |       |       |       |       |       |
| Gentamicin, GEN |       |       |       |       |       |
| Meropenem, MER |       |       |       |       |       |
| Nalidixic acid, NAL |       |       |       |       |       |
| Sulfonamides, SMX |       |       |       |       |       |
| Tetracycline, TET |       |       |       |       |       |
| Trimethoprim, TMP |       |       |       |       |       |
| Trimethoprim + sulfamethoxazole, SXT |       |       |       |       |       |

Regarding method used for antimicrobial susceptibility testing of *Salmonella* in this EQAS:

 [ ]  MIC – Microbroth dilution

 [ ]  MIC – Macro dilution (tubes)

 [ ]  MIC – Agar dilution

 [ ]  E-test

 [ ]  Disk diffusion

 [ ]  Tablets – Neo Sensitabs, Rosco

 Brand**:**

 Incubation conditions:      °C/     h

Regarding antisera used for serotyping of *Salmonella* in this EQAS:

#### Brand of antisera:

#### Comments on which antisera you think is required to complete your serotyping, or other comments:      **TEST FORM *– Salmonella***

|  |  |  |
| --- | --- | --- |
| Strain – *Salmonella* | Antimicrobial  | Interpretation |
| ≤> | Zone diameter (mm) orMIC-value (μg/ml) | S / I / R |
| WHO S-17.1\_\_\_\_\_     \_\_\_\_\_Serogroup\_\_\_\_\_     \_\_\_\_\_Serotype\_\_\_\_\_     \_\_\_\_\_Antigenic formula | Ampicillin, AMP |       |       |       |
| Cefotaxime, CTX |       |       |       |
| Cefoxitin, FOX |       |       |       |
| Ceftazidime, CAZ |       |       |       |
| Ceftriaxone, CRO |       |       |       |
| Chloramphenicol, CHL |       |       |       |
| Ciprofloxacin, CIP |       |       |       |
| Colistin, COL |       |       |       |
| Gentamicin, GEN |       |       |       |
| Meropenem, MER  |       |       |       |
| Nalidixic acid, NAL |       |       |       |
| Sulfonamides, SMX |       |       |       |
| Tetracycline, TET |       |       |       |
| Trimethoprim, TMP |       |       |       |
| Trimethoprim + sulfamethoxazole, SXT |       |       |       |

All strains displaying reduced susceptibility to cefotaxime (CTX), ceftazidime (CAZ), and/or ceftriaxone (CRO) could additionally be tested for ampC, ESBL- or carbapenemase-production. See further description in the protocol section 3.3.

|  |  |  |
| --- | --- | --- |
| Did you test for ESBL-production (ESBL-, AmpC, or carbapenemase-phenotypes)?[ ]  Yes [ ]  NoIs the strain ESBL-producing (ESBL-, AmpC, or carbapenemase-phenotypes)?[ ]  Yes [ ]  NoIndicate the phenotype of the strain: [please select one option][ ]  ESBL-phenotype[ ]  ESBL+AmpC-phenotype[ ]  AmpC-phenotype[ ]  Carbapenemase-phenotype[ ]  Other phenotype[ ]  No ESBL, AmpC or carbapenemase |  | **Details from laboratory testing** |
|  | **MIC, value or ratio** | **Disks, zone diameter increase** |
| **CTX:CTX/Cl** | [ ]  MIC ratio ≥ 8 (synergy)[ ]  MIC ratio < 8[ ]  Phantom zone (E-test) (synergy)[ ]  Deformation (E-test) (synergy)[ ]  Not determinable   | [ ]  Increase  ≥ 5 mm (synergy)[ ]  Increase  < 5 mm |
| **CAZ:CAZ/Cl** | [ ]  MIC ratio ≥ 8 (synergy)[ ]  MIC ratio < 8[ ]  Phantom zone (E-test) (synergy)[ ]  Deformation (E-test) (synergy)[ ]  Not determinable | [ ]  Increase  ≥ 5 mm (synergy)[ ]  Increase  < 5 mm |
|  |  |  |

Comments:

#### **TEST FORM *– Salmonella***

|  |  |  |
| --- | --- | --- |
| Strain – *Salmonella* | Antimicrobial  | Interpretation |
| ≤> | Zone diameter (mm) orMIC-value (μg/ml) | S / I / R |
| WHO S-17.2\_\_\_\_\_     \_\_\_\_\_Serogroup\_\_\_\_\_     \_\_\_\_\_Serotype\_\_\_\_\_     \_\_\_\_\_Antigenic formula | Ampicillin, AMP |       |       |       |
| Cefotaxime, CTX |       |       |       |
| Cefoxitin, FOX |       |       |       |
| Ceftazidime, CAZ |       |       |       |
| Ceftriaxone, CRO |       |       |       |
| Chloramphenicol, CHL |       |       |       |
| Ciprofloxacin, CIP |       |       |       |
| Colistin, COL |       |       |       |
| Gentamicin, GEN |       |       |       |
| Meropenem, MER  |       |       |       |
| Nalidixic acid, NAL |       |       |       |
| Sulfonamides, SMX |       |       |       |
| Tetracycline, TET |       |       |       |
| Trimethoprim, TMP |       |       |       |
| Trimethoprim + sulfamethoxazole, SXT |       |       |       |

All strains displaying reduced susceptibility to cefotaxime (CTX), ceftazidime (CAZ), and/or ceftriaxone (CRO) could additionally be tested for ampC, ESBL- or carbapenemase-production. See further description in the protocol section 3.3.

|  |  |  |
| --- | --- | --- |
| Did you test for ESBL-production (ESBL-, AmpC, or carbapenemase-phenotypes)?[ ]  Yes [ ]  NoIs the strain ESBL-producing (ESBL-, AmpC, or carbapenemase-phenotypes)?[ ]  Yes [ ]  NoIndicate the phenotype of the strain: [please select one option][ ]  ESBL-phenotype[ ]  ESBL+AmpC-phenotype[ ]  AmpC-phenotype[ ]  Carbapenemase-phenotype[ ]  Other phenotype[ ]  No ESBL, AmpC or carbapenemase |  | **Details from laboratory testing** |
|  | **MIC, value or ratio** | **Disks, zone diameter increase** |
| **CTX:CTX/Cl** | [ ]  MIC ratio ≥ 8 (synergy)[ ]  MIC ratio < 8[ ]  Phantom zone (E-test) (synergy)[ ]  Deformation (E-test) (synergy)[ ]  Not determinable   | [ ]  Increase  ≥ 5 mm (synergy)[ ]  Increase  < 5 mm |
| **CAZ:CAZ/Cl** | [ ]  MIC ratio ≥ 8 (synergy)[ ]  MIC ratio < 8[ ]  Phantom zone (E-test) (synergy)[ ]  Deformation (E-test) (synergy)[ ]  Not determinable | [ ]  Increase  ≥ 5 mm (synergy)[ ]  Increase  < 5 mm |
|  |  |  |

Comments:

#### **TEST FORM *– Salmonella***

|  |  |  |
| --- | --- | --- |
| Strain – *Salmonella* | Antimicrobial  | Interpretation |
| ≤> | Zone diameter (mm) orMIC-value (μg/ml) | S / I / R |
| WHO S-17.3\_\_\_\_\_     \_\_\_\_\_Serogroup\_\_\_\_\_     \_\_\_\_\_Serotype\_\_\_\_\_     \_\_\_\_\_Antigenic formula | Ampicillin, AMP |       |       |       |
| Cefotaxime, CTX |       |       |       |
| Cefoxitin, FOX |       |       |       |
| Ceftazidime, CAZ |       |       |       |
| Ceftriaxone, CRO |       |       |       |
| Chloramphenicol, CHL |       |       |       |
| Ciprofloxacin, CIP |       |       |       |
| Colistin, COL |       |       |       |
| Gentamicin, GEN |       |       |       |
| Meropenem, MER  |       |       |       |
| Nalidixic acid, NAL |       |       |       |
| Sulfonamides, SMX |       |       |       |
| Tetracycline, TET |       |       |       |
| Trimethoprim, TMP |       |       |       |
| Trimethoprim + sulfamethoxazole, SXT |       |       |       |

All strains displaying reduced susceptibility to cefotaxime (CTX), ceftazidime (CAZ), and/or ceftriaxone (CRO) could additionally be tested for ampC, ESBL- or carbapenemase-production. See further description in the protocol section 3.3.

|  |  |  |
| --- | --- | --- |
| Did you test for ESBL-production (ESBL-, AmpC, or carbapenemase-phenotypes)?[ ]  Yes [ ]  NoIs the strain ESBL-producing (ESBL-, AmpC, or carbapenemase-phenotypes)?[ ]  Yes [ ]  NoIndicate the phenotype of the strain: [please select one option][ ]  ESBL-phenotype[ ]  ESBL+AmpC-phenotype[ ]  AmpC-phenotype[ ]  Carbapenemase-phenotype[ ]  Other phenotype[ ]  No ESBL, AmpC or carbapenemase |  | **Details from laboratory testing** |
|  | **MIC, value or ratio** | **Disks, zone diameter increase** |
| **CTX:CTX/Cl** | [ ]  MIC ratio ≥ 8 (synergy)[ ]  MIC ratio < 8[ ]  Phantom zone (E-test) (synergy)[ ]  Deformation (E-test) (synergy)[ ]  Not determinable   | [ ]  Increase  ≥ 5 mm (synergy)[ ]  Increase  < 5 mm |
| **CAZ:CAZ/Cl** | [ ]  MIC ratio ≥ 8 (synergy)[ ]  MIC ratio < 8[ ]  Phantom zone (E-test) (synergy)[ ]  Deformation (E-test) (synergy)[ ]  Not determinable | [ ]  Increase  ≥ 5 mm (synergy)[ ]  Increase  < 5 mm |
|  |  |  |

Comments:

#### **TEST FORM *– Salmonella***

|  |  |  |
| --- | --- | --- |
| Strain – *Salmonella* | Antimicrobial  | Interpretation |
| ≤> | Zone diameter (mm) orMIC-value (μg/ml) | S / I / R |
| WHO S-17.4\_\_\_\_\_     \_\_\_\_\_Serogroup\_\_\_\_\_     \_\_\_\_\_Serotype\_\_\_\_\_     \_\_\_\_\_Antigenic formula | Ampicillin, AMP |       |       |       |
| Cefotaxime, CTX |       |       |       |
| Cefoxitin, FOX |       |       |       |
| Ceftazidime, CAZ |       |       |       |
| Ceftriaxone, CRO |       |       |       |
| Chloramphenicol, CHL |       |       |       |
| Ciprofloxacin, CIP |       |       |       |
| Colistin, COL |       |       |       |
| Gentamicin, GEN |       |       |       |
| Meropenem, MER  |       |       |       |
| Nalidixic acid, NAL |       |       |       |
| Sulfonamides, SMX |       |       |       |
| Tetracycline, TET |       |       |       |
| Trimethoprim, TMP |       |       |       |
| Trimethoprim + sulfamethoxazole, SXT |       |       |       |

All strains displaying reduced susceptibility to cefotaxime (CTX), ceftazidime (CAZ), and/or ceftriaxone (CRO) could additionally be tested for ampC, ESBL- or carbapenemase-production. See further description in the protocol section 3.3.

|  |  |  |
| --- | --- | --- |
| Did you test for ESBL-production (ESBL-, AmpC, or carbapenemase-phenotypes)?[ ]  Yes [ ]  NoIs the strain ESBL-producing (ESBL-, AmpC, or carbapenemase-phenotypes)?[ ]  Yes [ ]  NoIndicate the phenotype of the strain: [please select one option][ ]  ESBL-phenotype[ ]  ESBL+AmpC-phenotype[ ]  AmpC-phenotype[ ]  Carbapenemase-phenotype[ ]  Other phenotype[ ]  No ESBL, AmpC or carbapenemase |  | **Details from laboratory testing** |
|  | **MIC, value or ratio** | **Disks, zone diameter increase** |
| **CTX:CTX/Cl** | [ ]  MIC ratio ≥ 8 (synergy)[ ]  MIC ratio < 8[ ]  Phantom zone (E-test) (synergy)[ ]  Deformation (E-test) (synergy)[ ]  Not determinable   | [ ]  Increase  ≥ 5 mm (synergy)[ ]  Increase  < 5 mm |
| **CAZ:CAZ/Cl** | [ ]  MIC ratio ≥ 8 (synergy)[ ]  MIC ratio < 8[ ]  Phantom zone (E-test) (synergy)[ ]  Deformation (E-test) (synergy)[ ]  Not determinable | [ ]  Increase  ≥ 5 mm (synergy)[ ]  Increase  < 5 mm |
|  |  |  |

Comments:

#### **TEST FORM *– Salmonella***

|  |  |  |
| --- | --- | --- |
| Strain – *Salmonella* | Antimicrobial  | Interpretation |
| ≤> | Zone diameter (mm) orMIC-value (μg/ml) | S / I / R |
| WHO S-17.5\_\_\_\_\_     \_\_\_\_\_Serogroup\_\_\_\_\_     \_\_\_\_\_Serotype\_\_\_\_\_     \_\_\_\_\_Antigenic formula | Ampicillin, AMP |       |       |       |
| Cefotaxime, CTX |       |       |       |
| Cefoxitin, FOX |       |       |       |
| Ceftazidime, CAZ |       |       |       |
| Ceftriaxone, CRO |       |       |       |
| Chloramphenicol, CHL |       |       |       |
| Ciprofloxacin, CIP |       |       |       |
| Colistin, COL |       |       |       |
| Gentamicin, GEN |       |       |       |
| Meropenem, MER  |       |       |       |
| Nalidixic acid, NAL |       |       |       |
| Sulfonamides, SMX |       |       |       |
| Tetracycline, TET |       |       |       |
| Trimethoprim, TMP |       |       |       |
| Trimethoprim + sulfamethoxazole, SXT |       |       |       |

All strains displaying reduced susceptibility to cefotaxime (CTX), ceftazidime (CAZ), and/or ceftriaxone (CRO) could additionally be tested for ampC, ESBL- or carbapenemase-production. See further description in the protocol section 3.3.

|  |  |  |
| --- | --- | --- |
| Did you test for ESBL-production (ESBL-, AmpC, or carbapenemase-phenotypes)?[ ]  Yes [ ]  NoIs the strain ESBL-producing (ESBL-, AmpC, or carbapenemase-phenotypes)?[ ]  Yes [ ]  NoIndicate the phenotype of the strain: [please select one option][ ]  ESBL-phenotype[ ]  ESBL+AmpC-phenotype[ ]  AmpC-phenotype[ ]  Carbapenemase-phenotype[ ]  Other phenotype[ ]  No ESBL, AmpC or carbapenemase |  | **Details from laboratory testing** |
|  | **MIC, value or ratio** | **Disks, zone diameter increase** |
| **CTX:CTX/Cl** | [ ]  MIC ratio ≥ 8 (synergy)[ ]  MIC ratio < 8[ ]  Phantom zone (E-test) (synergy)[ ]  Deformation (E-test) (synergy)[ ]  Not determinable   | [ ]  Increase  ≥ 5 mm (synergy)[ ]  Increase  < 5 mm |
| **CAZ:CAZ/Cl** | [ ]  MIC ratio ≥ 8 (synergy)[ ]  MIC ratio < 8[ ]  Phantom zone (E-test) (synergy)[ ]  Deformation (E-test) (synergy)[ ]  Not determinable | [ ]  Increase  ≥ 5 mm (synergy)[ ]  Increase  < 5 mm |
|  |  |  |

Comments:

#### **TEST FORM *– Salmonella***

|  |  |  |
| --- | --- | --- |
| Strain – *Salmonella* | Antimicrobial  | Interpretation |
| ≤> | Zone diameter (mm) orMIC-value (μg/ml) | S / I / R |
| WHO S-17.6\_\_\_\_\_     \_\_\_\_\_Serogroup\_\_\_\_\_     \_\_\_\_\_Serotype\_\_\_\_\_     \_\_\_\_\_Antigenic formula | Ampicillin, AMP |       |       |       |
| Cefotaxime, CTX |       |       |       |
| Cefoxitin, FOX |       |       |       |
| Ceftazidime, CAZ |       |       |       |
| Ceftriaxone, CRO |       |       |       |
| Chloramphenicol, CHL |       |       |       |
| Ciprofloxacin, CIP |       |       |       |
| Colistin, COL |       |       |       |
| Gentamicin, GEN |       |       |       |
| Meropenem, MER  |       |       |       |
| Nalidixic acid, NAL |       |       |       |
| Sulfonamides, SMX |       |       |       |
| Tetracycline, TET |       |       |       |
| Trimethoprim, TMP |       |       |       |
| Trimethoprim + sulfamethoxazole, SXT |       |       |       |

All strains displaying reduced susceptibility to cefotaxime (CTX), ceftazidime (CAZ), and/or ceftriaxone (CRO) could additionally be tested for ampC, ESBL- or carbapenemase-production. See further description in the protocol section 3.3.

|  |  |  |
| --- | --- | --- |
| Did you test for ESBL-production (ESBL-, AmpC, or carbapenemase-phenotypes)?[ ]  Yes [ ]  NoIs the strain ESBL-producing (ESBL-, AmpC, or carbapenemase-phenotypes)?[ ]  Yes [ ]  NoIndicate the phenotype of the strain: [please select one option][ ]  ESBL-phenotype[ ]  ESBL+AmpC-phenotype[ ]  AmpC-phenotype[ ]  Carbapenemase-phenotype[ ]  Other phenotype[ ]  No ESBL, AmpC or carbapenemase |  | **Details from laboratory testing** |
|  | **MIC, value or ratio** | **Disks, zone diameter increase** |
| **CTX:CTX/Cl** | [ ]  MIC ratio ≥ 8 (synergy)[ ]  MIC ratio < 8[ ]  Phantom zone (E-test) (synergy)[ ]  Deformation (E-test) (synergy)[ ]  Not determinable   | [ ]  Increase  ≥ 5 mm (synergy)[ ]  Increase  < 5 mm |
| **CAZ:CAZ/Cl** | [ ]  MIC ratio ≥ 8 (synergy)[ ]  MIC ratio < 8[ ]  Phantom zone (E-test) (synergy)[ ]  Deformation (E-test) (synergy)[ ]  Not determinable | [ ]  Increase  ≥ 5 mm (synergy)[ ]  Increase  < 5 mm |
|  |  |  |

Comments:

#### **TEST FORM *– Salmonella***

|  |  |  |
| --- | --- | --- |
| Strain – *Salmonella* | Antimicrobial  | Interpretation |
| ≤> | Zone diameter (mm) orMIC-value (μg/ml) | S / I / R |
| WHO S-17.7\_\_\_\_\_     \_\_\_\_\_Serogroup\_\_\_\_\_     \_\_\_\_\_Serotype\_\_\_\_\_     \_\_\_\_\_Antigenic formula | Ampicillin, AMP |       |       |       |
| Cefotaxime, CTX |       |       |       |
| Cefoxitin, FOX |       |       |       |
| Ceftazidime, CAZ |       |       |       |
| Ceftriaxone, CRO |       |       |       |
| Chloramphenicol, CHL |       |       |       |
| Ciprofloxacin, CIP |       |       |       |
| Colistin, COL |       |       |       |
| Gentamicin, GEN |       |       |       |
| Meropenem, MER  |       |       |       |
| Nalidixic acid, NAL |       |       |       |
| Sulfonamides, SMX |       |       |       |
| Tetracycline, TET |       |       |       |
| Trimethoprim, TMP |       |       |       |
| Trimethoprim + sulfamethoxazole, SXT |       |       |       |

All strains displaying reduced susceptibility to cefotaxime (CTX), ceftazidime (CAZ), and/or ceftriaxone (CRO) could additionally be tested for ampC, ESBL- or carbapenemase-production. See further description in the protocol section 3.3.

|  |  |  |
| --- | --- | --- |
| Did you test for ESBL-production (ESBL-, AmpC, or carbapenemase-phenotypes)?[ ]  Yes [ ]  NoIs the strain ESBL-producing (ESBL-, AmpC, or carbapenemase-phenotypes)?[ ]  Yes [ ]  NoIndicate the phenotype of the strain: [please select one option][ ]  ESBL-phenotype[ ]  ESBL+AmpC-phenotype[ ]  AmpC-phenotype[ ]  Carbapenemase-phenotype[ ]  Other phenotype[ ]  No ESBL, AmpC or carbapenemase |  | **Details from laboratory testing** |
|  | **MIC, value or ratio** | **Disks, zone diameter increase** |
| **CTX:CTX/Cl** | [ ]  MIC ratio ≥ 8 (synergy)[ ]  MIC ratio < 8[ ]  Phantom zone (E-test) (synergy)[ ]  Deformation (E-test) (synergy)[ ]  Not determinable   | [ ]  Increase  ≥ 5 mm (synergy)[ ]  Increase  < 5 mm |
| **CAZ:CAZ/Cl** | [ ]  MIC ratio ≥ 8 (synergy)[ ]  MIC ratio < 8[ ]  Phantom zone (E-test) (synergy)[ ]  Deformation (E-test) (synergy)[ ]  Not determinable | [ ]  Increase  ≥ 5 mm (synergy)[ ]  Increase  < 5 mm |
|  |  |  |

Comments:

#### **TEST FORM *– Salmonella***

|  |  |  |
| --- | --- | --- |
| Strain – *Salmonella* | Antimicrobial  | Interpretation |
| ≤> | Zone diameter (mm) orMIC-value (μg/ml) | S / I / R |
| WHO S-17.8\_\_\_\_\_     \_\_\_\_\_Serogroup\_\_\_\_\_     \_\_\_\_\_Serotype\_\_\_\_\_     \_\_\_\_\_Antigenic formula | Ampicillin, AMP |       |       |       |
| Cefotaxime, CTX |       |       |       |
| Cefoxitin, FOX |       |       |       |
| Ceftazidime, CAZ |       |       |       |
| Ceftriaxone, CRO |       |       |       |
| Chloramphenicol, CHL |       |       |       |
| Ciprofloxacin, CIP |       |       |       |
| Colistin, COL |       |       |       |
| Gentamicin, GEN |       |       |       |
| Meropenem, MER  |       |       |       |
| Nalidixic acid, NAL |       |       |       |
| Sulfonamides, SMX |       |       |       |
| Tetracycline, TET |       |       |       |
| Trimethoprim, TMP |       |       |       |
| Trimethoprim + sulfamethoxazole, SXT |       |       |       |

All strains displaying reduced susceptibility to cefotaxime (CTX), ceftazidime (CAZ), and/or ceftriaxone (CRO) could additionally be tested for ampC, ESBL- or carbapenemase-production. See further description in the protocol section 3.3.

|  |  |  |
| --- | --- | --- |
| Did you test for ESBL-production (ESBL-, AmpC, or carbapenemase-phenotypes)?[ ]  Yes [ ]  NoIs the strain ESBL-producing (ESBL-, AmpC, or carbapenemase-phenotypes)?[ ]  Yes [ ]  NoIndicate the phenotype of the strain: [please select one option][ ]  ESBL-phenotype[ ]  ESBL+AmpC-phenotype[ ]  AmpC-phenotype[ ]  Carbapenemase-phenotype[ ]  Other phenotype[ ]  No ESBL, AmpC or carbapenemase |  | **Details from laboratory testing** |
|  | **MIC, value or ratio** | **Disks, zone diameter increase** |
| **CTX:CTX/Cl** | [ ]  MIC ratio ≥ 8 (synergy)[ ]  MIC ratio < 8[ ]  Phantom zone (E-test) (synergy)[ ]  Deformation (E-test) (synergy)[ ]  Not determinable   | [ ]  Increase  ≥ 5 mm (synergy)[ ]  Increase  < 5 mm |
| **CAZ:CAZ/Cl** | [ ]  MIC ratio ≥ 8 (synergy)[ ]  MIC ratio < 8[ ]  Phantom zone (E-test) (synergy)[ ]  Deformation (E-test) (synergy)[ ]  Not determinable | [ ]  Increase  ≥ 5 mm (synergy)[ ]  Increase  < 5 mm |
|  |  |  |

Comments:

#### **TEST FORM – *E. coli* reference strain**

Susceptibility testing of *E. coli* reference strain ATCC 25922

|  |  |  |
| --- | --- | --- |
| Strain | Antimicrobial  | Zone diameter (mm) or MIC-value (μg/ml) |
| *E. coli* ATCC 25922 | Ampicillin, AMP |       |
| Cefotaxime, CTX |       |
| Cefoxitin, FOX |       |
| Ceftazidime, CAZ |       |
| Ceftriaxone, CRO |       |
| Chloramphenicol, CHL |       |
| Ciprofloxacin, CIP |       |
| Colistin, COL |       |
| Gentamicin, GEN |       |
| Meropenem, MER |       |
| Nalidixic acid, NAL |       |
| Sulfamethoxazole, SMX |       |
| Tetracycline. TET |       |
| Trimethoprim, TMP |       |
| Trimethoprim + Sulphonamides , SXT |       |